Nasdaq · Healthcare
ACADIA PHARMACEUTICALS INC (ACAD)
As-reported financials and recent SEC filings for ACADIA PHARMACEUTICALS INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$1.07B
Net income
$391.0M
Net margin
36.5%
Diluted EPS
$2.30
ROE
31.9%
P/E (TTM)
11.5×
Market cap
$4.34B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.07B | $957.8M | $726.4M | $517.2M | $484.1M |
| Gross profit | $982.5M | $876.0M | — | — | — |
| Operating income | $104.8M | $230.8M | $-73.4M | $-223.6M | $-170.4M |
| Net income | $391.0M | $226.5M | $-61.3M | $-216.0M | $-167.9M |
| Diluted EPS | $2.30 | $1.36 | $-0.37 | $-1.34 | $-0.00 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
1442026-06-26
View on EDGAR →S-82026-06-10
View on EDGAR →42026-06-02
View on EDGAR →42026-06-01
View on EDGAR →42026-06-01
View on EDGAR →42026-06-01
View on EDGAR →42026-06-01
View on EDGAR →42026-06-01
View on EDGAR →Go deeper on ACAD
Search ACADIA PHARMACEUTICALS INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.